Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Lorus Therapeutics Receives Patent Approval For Anticancer Drug LOR-253

Lorus Therapeutics Inc. (LOR.TO: Quote) said Wednesday it has got the approval of the U.S. Patent and Trademark Office for its patent regarding the lead small molecule anticancer drug LOR-253.

The patent, which was originally set to expire in May 2026, was granted a patent adjustment that extends its expiry date to February 2028.

The US patent covers LOR-253 composition of matter and methods of treating cancer. Patents with similar protection for LOR-253 have been issued in Canada and Australia, and are pending in Europe, Japan, and China.

LOR-253 is in a Phase I clinical trial that assesses the safety profile and antitumor activity of LOR-253. Patients with advanced or metastatic solid tumors who are unresponsive to conventional therapy, or for which no effective therapy is available, are currently being recruited for this clinical study.

Click here to receive FREE breaking news email alerts for Lorus Therapeutics and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Stocks have fluctuated over the course of the trading day on Thursday, as traders continue to digest yesterday's monetary policy announcement from the Federal Reserve as well as better than expected third quarter GDP data. Hundreds of protesters stormed Burkina Faso's parliament on Thursday and set fire to the building, preventing the lawmakers from considering a bill to extend the president's 27-year rule. Security forces opened fire on protesters, as they looted computers and televisions in the National Assembly, news agencies reported. The angry crowd then marched towards the President's office, before they were U.S. economic activity increased by more than expected in the third quarter of 2014, according to a report released by the Commerce Department on Thursday. The Commerce Department said GDP increased by 3.5 percent in the third quarter compared to 3.0 percent growth expected by economists.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.